Cargando…
A Critical YAP in Malignancy of HCC Is Regulated by Evodiamine
Liver cancer has relatively few early symptoms and is usually diagnosed in the advanced stage. Sorafenib is the only first-line anticancer drug approved by the Food and Drug Administration (FDA) for advanced HCC; however, its use is limited due to resistance. Therefore, the development of new drugs...
Autores principales: | Yun, Un-Jung, Bae, Su-Jin, Song, Yu-Rim, Kim, Young-Woo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8837083/ https://www.ncbi.nlm.nih.gov/pubmed/35163776 http://dx.doi.org/10.3390/ijms23031855 |
Ejemplares similares
-
Angelica gigas NAKAI and Its Active Compound, Decursin, Inhibit Cellular Injury as an Antioxidant by the Regulation of AMP-Activated Protein Kinase and YAP Signaling
por: Song, Yu-Rim, et al.
Publicado: (2022) -
Pharmacological Actions of Multi-Target-Directed Evodiamine
por: Yu, Hui, et al.
Publicado: (2013) -
Evodiamine Inhibits Helicobacter pylori Growth and Helicobacter pylori-Induced Inflammation
por: Yang, Ji Yeong, et al.
Publicado: (2021) -
Evodiamine Eliminates Colon Cancer Stem Cells via Suppressing Notch and Wnt Signaling
por: Kim, Hyejin, et al.
Publicado: (2019) -
Systemic and molecular analysis dissect the red ginseng induction of apoptosis and autophagy in HCC as mediated with AMPK
por: Kim, Young Woo, et al.
Publicado: (2023)